ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 737건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 737 | Not yet recruiting | "Efesovir" (FS-1) for COVID-19, Phase 2 | Covid19 | Drug: Efesovir | Phase 2 | Scientific Center for Anti-infectious Drugs, Kazakhstan | INDUSTRY | 62 | All | 18 Years ~ 59 Years | Semey Medical University, Semey, East-Kazakhstan Region, Kazakhstan |
| 736 | Completed | A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIAL | COVID-19 | Biological: hAd5-S-Fusion+N-ETSD Biological: Placebo (0.9% (w/v) saline) |
Phase 3 | ImmunityBio, Inc. | INDUSTRY | 35 | All | 16 Years ~ 80 Years | Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States |
| 735 | Completed | A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients | Coronavirus Disease 2019(COVID-19) | Biological: HH-120 Nasal Spray | Not Applicable | Beijing Ditan Hospital | OTHER | 111 | All | 18 Years ~ 65 Years | Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China |
| 734 | Completed | A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 | COVID-19 | Drug: SIM0417 Drug: Placebo |
Phase 3 | Jiangsu Simcere Pharmaceutical Co., Ltd. | INDUSTRY | 1208 | All | 18 Years | Hefei First People's Hospital, Hefei, Anhui, China Beijing Ditan Hospital Captial Medical University, Beijing, Beijing, China Chongqing Public Health Medical Center, Chongqing, Chongqing, China The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China Guangzhou Eighth People's Hospital Guangzhou Medical University, Guangzhou, Guangdong, China Maoming People's Hospital, Maoming, Guangdong, China Qingyuan People's Hospital, Qingyuan, Guangdong, China The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, China The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, China GuiZhou Province People's Hospital, Guiyang, Guizhou, China Haikou people's Hospital, Haikou, Hainan, China Hainan Third People's Hospital, Sanya, Hainan, China Mudanjiang Kangan Hospital, Mudanjiang, Heilongjiang, China Wuhan Jinyintan Hospital, Wuhan, Hubei, China The First Hospital of Changsha, Changsha, Hunan, China The Second Hospital of Nanjing, Nanjing, Jiangsu, China ZhongDa Hospital SouthEast University, Nanjing, Jiangsu, China The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China Taizhou People's Hospital, Taizhou, Jiangsu, China Wuxi No.5 People's Hospital, Wuxi, Jiangsu, China Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China The Third People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China The Sixth People's Hospital of ShenYang, Shenyang, Liaoning, China Shandong Public Health Clinical Center, Jinan, Shandong, China Shanghai Public Health Clinical Center, Shanghai, Shanghai, China Public health clinical center of Chengdu, Chengdu, Sichuan, China Suining Central Hospital, Suining, Sichuan, China Tianjin first center hospital, Tianjin, Tianjin, China Affliated Hangzhou XiXi Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China Huzhou Central Hospital, Huzhou, Zhejiang, China HwaMei Hospital University of Chinese Academy of Sciences, Ningbo, Zhejiang, China Wenzhou Central Hospital, Wenzhou, Zhejiang, China |
| 733 | Completed | A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster | SARS-CoV-2 Infection | Biological: Recombinant COVID-19 Vaccine (Sf9 Cell) Biological: COVID-19 Vaccine (Vero Cell), Inactivated |
Not Applicable | WestVac Biopharma Co., Ltd., West China Hospital | INDUSTRY | 120 | All | 18 Years ~ 60 Years | West China Hospital of Sichuan University, Chengdu, Sichuan, China |
| 732 | Completed | A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19 | COVID-19 | Drug: Convalesscent Plasma | Phase 2 | Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen | OTHER | 106 | All | 18 Years ~ 75 Years | University Hospital Ulm, Ulm, Baden-Wurttmberg, Germany University Hopsital Frankfurt, Frankfurt, Hessia, Germany Saarland University Hospital, Homburg, Saarland, Germany University Hospital Berlin, Charite, Berlin, Germany Universitiy Hospital Dresden, Dresden, Germany University Dusseldorf, Dusseldorf, Germany University Hospital Freiburg, Freiburg, Germany University Hospital Gießen, Gießen, Germany University Hopsital Greifswald, Greifswald, Germany Stadtisches Klinikum Karslruhe, Karlsruhe, Germany Universtity Hospital Schleswig-Holstein, Kiel, Germany Universtity Hospital Schleswig-Holstein, Lubeck, Germany University Hospital Mannheim, Mannheim, Germany University Hospital Marburg, Marburg, Germany Klinikum Stuttgart, Stuttgart, Germany University Hospital Tubingen, Tubingen, Germany |
| 731 | Completed | A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) | SARS-CoV-2 Pneumonia | Biological: Recombinant COVID-19 vaccine (Sf9 cell) | Not Applicable | WestVac Biopharma Co., Ltd. | INDUSTRY | 1000 | All | 18 Years ~ 59 Years | Jiangsu Provincial Center for Disease Control and Prevention, Huai'an, Jiangsu, China |
